Stefan Bleher

Stefan Bleher

Auto-generated profile, based on publicly available information

Stefan Bleher

Lonza AG, Drug Product Services, Hochbergerstr. 60G, 4057 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2019 in Small
Verified
Journal Article
Open access
PDF file
SBStefan Bleher
Stefan Bleher
JBJonas Buck
Jonas Buck
CMChristian Muhl
Christian Muhl
SSSandro Sieber
Sandro Sieber
SBSabine Barnert
Sabine Barnert
RSRegine Süss
Regine Süss
Circulation lifetime is a crucial parameter for a successful therapy with nanoparticles. Reduction and alteration of opsonization profiles by surface modification of nanoparticles is the main strategy to achieve this objective. In clinical settings, PEGylation is the most relevant strategy to enhance blood circulation, yet it has drawbacks, including hypersensitivity reactions in some patients treated with PEGylated nanoparticles, which fuel the search for alternative strategies. In this work, lipopolysarcosine derivatives (BA‐pSar, bisalkyl polysarcosine) with precise chain lengths and low polydispersity indices are synthesized, characterized, and incorporated into the bilayer of preformed liposomes via a post insertion technique. Successful incorporation of BA‐pSar can be realized in a clinically relevant liposomal formulation. Furthermore, BA‐pSar provides excellent surface charge shielding potential for charged liposomes and renders their surface neutral. Pharmacokinetic investigations in a zebrafish model show enhanced circulation properties and reduction in macrophage recognition, matching the behavior of PEGylated liposomes. Moreover, complement activation, which is a key factor in hypersensitivity reactions caused by PEGylated liposomes, can be reduced by modifying the surface of liposomes with an acetylated BA‐pSar derivative. Hence, this study presents an alternative surface modification strategy with similar benefits as the established PEGylation of nanoparticles, but with the potential of reducing its drawbacks.

9 December 2016 in Polymers
Verified
Journal Article
Open access
PDF file
BWBennjamin Weber
Bennjamin Weber
CSChristine Seidl
Christine Seidl
DSDavid Schwiertz
David Schwiertz
MSMartin Scherer
Martin Scherer
SBStefan Bleher
Stefan Bleher
Matthias BarzMatthias Barz
Matthias Barz
Amphiphiles and, in particular, PEGylated lipids or alkyl ethers represent an important class of non-ionic surfactants and have become key ingredients for long-circulating (“stealth”) liposomes. While poly-(ethylene glycol) (PEG) can be considered the gold standard for stealth-like materials, it is known to be neither a bio-based nor biodegradable material. In contrast to PEG, polysarcosine (PSar) is based on the endogenous amino acid sarcosine (N-methylated glycine), but has also demonstrated stealth-like properties in vitro, as well as in vivo. In this respect, we report on the synthesis and characterization of polysarcosine based lipids with C14 and C18 hydrocarbon chains and their end group functionalization. Size exclusion chromatography (SEC) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis reveals that lipopeptoids with a degree of polymerization between 10 and 100, dispersity indices around 1.1, and the absence of detectable side products are directly accessible by nucleophilic ring opening polymerization (ROP). The values for the critical micelle concentration for these lipopolymers are between 27 and 1181 mg/L for the ones with C18 hydrocarbon chain or even higher for the C14 counterparts. The lipopolypeptoid based micelles have hydrodynamic diameters between 10 and 25 nm, in which the size scales with the length of the PSar block. In addition, C18PSar50 can be incorporated in 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) monolayers up to a polymer content of 3%. Cyclic compression and expansion of the monolayer showed no significant loss of polymer, indicating a stable monolayer. Therefore, lipopolypeptoids can not only be synthesized under living conditions, but my also provide a platform to substitute PEG-based lipopolymers as excipients and/or in lipid formulations.

1 March 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KGKathrin Gregoritza
Kathrin Gregoritza
SCSi Kai Cai
Si Kai Cai
MSMatej Siketanc
Matej Siketanc
AWAnne Woehr
Anne Woehr
VLVanessa Lebouc
Vanessa Lebouc
AAAndrea Allmendinger
Andrea Allmendinger

17 January 2026 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KWKlaus Wuchner
Klaus Wuchner
FNFelix Nikels
Felix Nikels
PGPatrick Garidel
Patrick Garidel
KBKaroline Bechtold-Peters
Karoline Bechtold-Peters
SGSanjay Gupta
Sanjay Gupta
SBStefan Bleher
Stefan Bleher